Risks small between HCV patients’ use of DAAs, neuropsychiatric events

Risks small between HCV patients’ use of DAAs, neuropsychiatric events

Sockalingam S. BMC Gastroenterol. 2013;doi:10.1186/1471-230X-13-86.

May 24, 2013
The risks for neuropsychiatric adverse events among patients with hepatitis C virus being treated with direct-acting antivirals appear minimal, but the risks for drug-drug interactions are high, according to recent study results.

Researchers conducted a literature search of PubMed from 2000 to April 2013 using the search terms, “hepatitis C” and “boceprevir” or “telaprevir,” along with “mental disorders,” “psychotropic drugs” and “drug interactions.” The analysis was designed to evaluate studies on neuropsychiatric adverse effects as a result of direct-acting antivirals (DAAs) and drug-drug interactions (DDIs) involving psychotropic medications and DAAs among hepatitis C virus (HCV) patients.

Continue Reading @ Healio